CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will host a webinar to provide details of the Company’s recently initiated Phase I clinical trial in the U.S. and Phase I/II clinical trial in the EU, both evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs.Read more
On Friday 23rd June, as part of the annual MRC Festival of Medical Research, the MRC Harwell Institute will host a Patient Open Day. Patients, their families and representatives who are interested in finding out more about primary scientific research, the relationship between genes and disease, and how mice are used in medical research are invited to attend.Read more
If you or your family member(s) receive care and services linked to an ultra-rare disease, such as Niemann-Pick, we need your help.
In order to bring about change and improvement in the care and services you receive, Niemann-Pick UK has been asked to provide feedback to NHS England. By participating in a short, but highly important survey, you could help to influence this process and enhance future care for those affected by Niemann-Pick and other ultra-rare diseases.Read more
You may recall that Niemann-Pick UK has been supporting Aston University in their work to deliver a research study titled “Development of health-related quality of life scales for patients and parents affected by Niemann-Pick Disease Type C”, which aims to bring benefits for the NP-C community.
This study has ethical and R&D approvals through the appropriate UK academic channels and in order to make further progress, research student Lydia needs your help.Read more